http://orcid.org/0000-0001-8553-6995
References
- Calza L, Danese I, Magistrelli E, et al. Dual raltegravir–darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors. HIV Clin Trials. 2016;17(1):38–47.
- Calza L, Cafaggi M, Colangeli V, et al. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy. Infect Dis (Auckl). 2018;50(5):352–360.
- Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384(9958):1942–1951.
- Madeddu G, Rusconi S, Cozzi-Lepri A, et al. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL. Infection. 2017;45(4):521–528.
- Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608–1618.
- Sterrantino G, Zaccarelli M, Di Biagio A, et al. Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database. Infection. 2015;43(3):339–343.
- Burgos J, Crespo M, Falco V, et al. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients. J Antimicrob Chemother. 2012;67(10):2479–2486.
- Capetti AF, Piconi S, Landonio S, et al. Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? JAIDS J Acquir Immune Defic Syndr. 2009;50(2):233–234.
- Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568):1169–1178.
- Banhegyi D, Katlama C, Arns da Cunha C, et al. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res. 2012;10(2):171–181.
- de Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24(3):379–388.
- De Meyer S, Lathouwers E, Dierynck I, et al. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS. 2009;23(14):1829–1840.
- Curran A, Monteiro P, Domingo P, et al. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group. J Antimicrob Chemother. 2014;69(5):1390–1396.
- Allavena C, Deschanvres C, Peytavin G, et al. Factors associated with therapeutic failure of 2-drug regimens, DAT’AIDS cohort [Abstract number 493]. CROI. 2019.
- Gagliardini R, Ciccullo A, Borghetti A, et al. Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study. Open Forum Infect Dis. 2018;5:1–8.
- Blanco JL, Gonzalez-Cordón A, Llibre JM, et al. Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir. Antivir Ther. 2014;20(5):487–492.
- Clutter DS, Jordan MR, Bertagnolio S, et al. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307.